JNJ - Johnson & Johnson Stock Price, News & Analysis

$137.29 -1.05 (-0.76 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$138.34
Today's Range$136.60 - $138.38
52-Week Range$109.32 - $144.35
Volume3.92 million shs
Average Volume5.89 million shs
Market Capitalization$366.03 billion
P/E Ratio19.38
Dividend Yield2.44%
Beta0.82

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:JNJ
CUSIP47816010

Debt

Debt-to-Equity Ratio0.36%
Current Ratio1.32%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E Ratio19.38
Forward P/E Ratio18.86
P/E Growth2.81

Sales & Book Value

Annual Sales$71.89 billion
Price / Sales5.13
Cash Flow$8.22 per share
Price / Cash16.71
Book Value$27.54 per share
Price / Book4.99

Dividend

Annual Dividend$3.36
Dividend Yield2.4%

Profitability

Trailing EPS$5.76
Net Income$16.54 billion
Net Margins21.28%
Return on Equity27.38%
Return on Assets13.20%

Miscellaneous

Employees126,400
Outstanding Shares2,686,520,000

Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Thursday, October 19th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share on Tuesday, December 12th. This represents a $3.36 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Monday, November 27th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Tuesday, October, 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.80 by $0.10. The business earned $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.68 EPS. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, October, 17th. The company provided earnings per share guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

19 equities research analysts have issued twelve-month target prices for Johnson & Johnson's shares. Their forecasts range from $110.00 to $165.00. On average, they expect Johnson & Johnson's share price to reach $143.56 in the next year. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. However, J&J’s shares have underperformed the industry this year so far. Headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline amid intense competition.  Estimates have remained mostly stable ahead of the Q3 results. J&J has a positive record of earnings surprises in recent quarters." (10/4/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS Group AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
  • 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
  • Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director (Age 64)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.36%), Ameriprise Financial Inc. (0.65%), Legal & General Group Plc (0.54%), Schwab Charles Investment Management Inc. (0.45%), Fisher Asset Management LLC (0.44%) and Swiss National Bank (401,574.66%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Prudential Financial Inc., American Century Companies Inc., Macquarie Group Ltd., Schroder Investment Management Group, State of Tennessee Treasury Department, Artisan Partners Limited Partnership and California State Teachers Retirement System. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, APG Asset Management N.V., Assenagon Asset Management S.A., Sanders Capital LLC, Janus Henderson Group PLC, Capital International Investors, Schwab Charles Investment Management Inc. and Caisse DE Depot ET Placement DU Quebec. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $137.29.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $366.03 billion and generates $71.89 billion in revenue each year. The company earns $16.54 billion in net income (profit) each year or $5.76 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is 1 Johnson And Johnson Plz, NEW BRUNSWICK, NJ 08933-0001, United States. The company can be reached via phone at +1-732-5242455.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  496 (Vote Outperform)
Underperform Votes:  600 (Vote Underperform)
Total Votes:  1,096
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Johnson & Johnson (NYSE:JNJ)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.32)
Consensus Price Target: $143.56 (4.56% upside)

Consensus Price Target History for Johnson & Johnson (NYSE:JNJ)

Price Target History for Johnson & Johnson (NYSE:JNJ)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Citigroup Inc.Boost Price TargetBuy$140.00 -> $149.00N/AView Rating Details
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 -> $154.00N/AView Rating Details
10/16/2017Jefferies Group LLCBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017Barclays PLCBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017Cowen and CompanyReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 -> $155.00N/AView Rating Details
10/18/2017BMO Capital MarketsReiterated RatingOutperform -> Positive$145.00 -> $152.00N/AView Rating Details
10/18/2017Stifel NicolausBoost Price TargetHold -> Hold$140.00 -> $142.00N/AView Rating Details
10/18/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$144.00 -> $147.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/20/2017Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
8/16/2017J P Morgan Chase & CoBoost Price TargetOverweight$140.00 -> $148.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
11/28/2016Bank of America CorporationReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Johnson & Johnson (NYSE:JNJ)

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018$1.72N/AView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $7.08
2018 EPS Consensus Estimate: $7.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20172$1.75$1.86$1.81
Q3 20171$1.84$1.84$1.84
Q4 20171$1.69$1.69$1.69
Q1 20181$1.99$1.99$1.99
Q2 20181$2.01$2.01$2.01
Q3 20181$2.18$2.18$2.18
Q4 20181$1.81$1.81$1.81
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Johnson & Johnson (NYSE:JNJ)

Next Dividend:12/12/2017
Annual Dividend:$3.36
Dividend Yield:2.45%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:58.33% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
42.80% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE JNJ)

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.61%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Insider Trades by Quarter for Johnson & Johnson (NYSE JNJ)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Johnson & Johnson (NYSE JNJ)

Source:
DateHeadline
The case for Johnson & Johnson - Motley FoolThe case for Johnson & Johnson - Motley Fool
www.fool.com - November 22 at 1:26 AM
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth - Seeking AlphaJohnson & Johnson: Dividend King With Good Total Return And Dividend Growth - Seeking Alpha
seekingalpha.com - November 22 at 1:26 AM
J&J drug succeeds in newly diagnosed multiple myeloma patients-studyJ&J drug succeeds in newly diagnosed multiple myeloma patients-study
finance.yahoo.com - November 22 at 1:26 AM
Interesting July 2018 Stock Options for JNJ - NasdaqInteresting July 2018 Stock Options for JNJ - Nasdaq
www.nasdaq.com - November 21 at 1:34 AM
Expanded use of Johnson & Johnsons prostate cancer med Zytiga OKd in Europe - Seeking AlphaExpanded use of Johnson & Johnson's prostate cancer med Zytiga OK'd in Europe - Seeking Alpha
seekingalpha.com - November 21 at 1:34 AM
How the Pricing Outlook in International Medical Technology Impacts JNJ TodayHow the Pricing Outlook in International Medical Technology Impacts JNJ Today
finance.yahoo.com - November 21 at 1:34 AM
Johnson & Johnson to Participate in the Citi 2017 Global Healthcare ConferenceJohnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference
finance.yahoo.com - November 21 at 1:34 AM
A Look at Merck’s Cardiovascular Portfolio in 3Q17A Look at Merck’s Cardiovascular Portfolio in 3Q17
finance.yahoo.com - November 21 at 1:34 AM
Stay away from big pharma?Stay away from big pharma?
finance.yahoo.com - November 21 at 1:34 AM
The Right Time To Buy Johnson & JohnsonThe Right Time To Buy Johnson & Johnson
seekingalpha.com - November 18 at 3:16 AM
How J&J Can Be A $150 StockHow J&J Can Be A $150 Stock
finance.yahoo.com - November 18 at 3:16 AM
J&J wins California lawsuit claiming asbestos in talc caused cancerJ&J wins California lawsuit claiming asbestos in talc caused cancer
finance.yahoo.com - November 18 at 3:16 AM
Gauging JNJ’s Recovery from the 3Q17 HurricanesGauging JNJ’s Recovery from the 3Q17 Hurricanes
finance.yahoo.com - November 18 at 3:15 AM
Johnson & Johnson’s (JNJ) Healthy Quant Score Keep it a BuyJohnson & Johnson’s (JNJ) Healthy Quant Score Keep it a Buy
investorplace.com - November 17 at 10:54 AM
Johnson & Johnson’s (JNJ) Healthy Quant Score Keep it a BuyJohnson & Johnson’s (JNJ) Healthy Quant Score Keep it a Buy
investorplace.com - November 17 at 10:52 AM
J&J wins California lawsuit claiming asbestos in baby powder caused cancer - Seeking AlphaJ&J wins California lawsuit claiming asbestos in baby powder caused cancer - Seeking Alpha
seekingalpha.com - November 17 at 9:17 AM
Johnson & Johnson: Does This Dividend Giant Still Offer Value ... - Seeking AlphaJohnson & Johnson: Does This Dividend Giant Still Offer Value ... - Seeking Alpha
seekingalpha.com - November 15 at 3:40 AM
Johnson & Johnsons (JNJ) Earnings Visibility Makes it Buy - Investorplace.comJohnson & Johnson's (JNJ) Earnings Visibility Makes it Buy - Investorplace.com
investorplace.com - November 11 at 7:49 PM
Johnson & Johnson CEO: Washington needs to work with us f...Johnson & Johnson CEO: Washington needs to work with us f...
finance.yahoo.com - November 11 at 2:44 PM
JNJ CEO: Need to work with Washington for 'smart tax poli...JNJ CEO: Need to work with Washington for 'smart tax poli...
finance.yahoo.com - November 11 at 2:43 PM
Zimmer Biomet’s Knee Sales in 3Q17: What’s Ahead?Zimmer Biomet’s Knee Sales in 3Q17: What’s Ahead?
finance.yahoo.com - November 11 at 2:43 PM
Johnson & Johnson CEO reveals the leadership lessons he learned at West PointJohnson & Johnson CEO reveals the leadership lessons he learned at West Point
www.cnbc.com - November 11 at 12:28 PM
 Analysts Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.21 Billion Analysts Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.21 Billion
www.americanbankingnews.com - November 10 at 11:12 AM
Johnson & Johnson’s (JNJ) Earnings Visibility Makes it BuyJohnson & Johnson’s (JNJ) Earnings Visibility Makes it Buy
investorplace.com - November 10 at 7:28 AM
Johnson & Johnsons Stelara successful in mid-stage lupus study - Seeking AlphaJohnson & Johnson's Stelara successful in mid-stage lupus study - Seeking Alpha
seekingalpha.com - November 8 at 11:07 AM
What Lies in Store for Pharma ETFs?What Lies in Store for Pharma ETFs?
finance.yahoo.com - November 8 at 11:07 AM
Johnson & Johnson -- Moodys assigns Aaa to J&Js sr. notes; stable outlookJohnson & Johnson -- Moody's assigns Aaa to J&J's sr. notes; stable outlook
finance.yahoo.com - November 8 at 11:07 AM
Johnson & Johnson (JNJ) Expected to Announce Earnings of $1.72 Per ShareJohnson & Johnson (JNJ) Expected to Announce Earnings of $1.72 Per Share
www.americanbankingnews.com - November 8 at 5:28 AM
Broker Darlings Of The Dow: Johnson & Johnson Ranks As A Top 15 Analyst PickBroker Darlings Of The Dow: Johnson & Johnson Ranks As A Top 15 Analyst Pick
www.thestreet.com - November 7 at 6:08 AM
Johnson & Johnson (JNJ) & Opko Health (OPK) Head to Head ComparisonJohnson & Johnson (JNJ) & Opko Health (OPK) Head to Head Comparison
www.americanbankingnews.com - November 7 at 3:28 AM
Johnson & Johnson (JNJ) Receives Average Rating of "Hold" from AnalystsJohnson & Johnson (JNJ) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 6 at 8:04 AM
Bayer in bid to broaden use of anti-clotting drug XareltoBayer in bid to broaden use of anti-clotting drug Xarelto
finance.yahoo.com - November 6 at 5:41 AM
Why the Healthcare Sector Struggled in OctoberWhy the Healthcare Sector Struggled in October
finance.yahoo.com - November 5 at 7:38 PM
A Dividend ETF For November And BeyondA Dividend ETF For November And Beyond
finance.yahoo.com - November 5 at 7:38 PM
Johnson & Johnson: Not Overvalued Per FCF Standpoint - Seeking AlphaJohnson & Johnson: Not Overvalued Per FCF Standpoint - Seeking Alpha
seekingalpha.com - November 3 at 11:52 AM
Superior Quant Score Keeps Johnson & Johnson (JNJ) a Buy - Investorplace.comSuperior Quant Score Keeps Johnson & Johnson (JNJ) a Buy - Investorplace.com
www.investorplace.com - November 3 at 11:52 AM
Superior Quant Score Keeps Johnson & Johnson (JNJ) a BuySuperior Quant Score Keeps Johnson & Johnson (JNJ) a Buy
investorplace.com - November 3 at 8:04 AM
Reviewing Johnson & Johnson (JNJ) & Its PeersReviewing Johnson & Johnson (JNJ) & Its Peers
www.americanbankingnews.com - November 2 at 8:42 AM
Dividend Aristocrats In Focus Part 27: Johnson & JohnsonDividend Aristocrats In Focus Part 27: Johnson & Johnson
seekingalpha.com - November 1 at 1:55 AM
Investor Group Presses Drugmakers, Distributors Over OpioidsInvestor Group Presses Drugmakers, Distributors Over Opioids
finance.yahoo.com - November 1 at 1:55 AM
New Jersey Joins States Suing Purdue Pharma for Opioid MarketingNew Jersey Joins States Suing Purdue Pharma for Opioid Marketing
finance.yahoo.com - November 1 at 1:55 AM
One Put, One Call Option To Know About for Johnson & Johnson - NasdaqOne Put, One Call Option To Know About for Johnson & Johnson - Nasdaq
www.nasdaq.com - October 30 at 11:41 PM
Corporate deal-making driven by fast technological changeCorporate deal-making driven by fast technological change
marketbeat.com - October 30 at 7:39 AM
High-End Earnings Visibility Analytics Raise Ranking of Johnson & Johnson (JNJ) to Strong BuyHigh-End Earnings Visibility Analytics Raise Ranking of Johnson & Johnson (JNJ) to Strong Buy
investorplace.com - October 27 at 7:24 AM
High-End Earnings Visibility Analytics Raise Ranking of Johnson & Johnson (JNJ) to Strong BuyHigh-End Earnings Visibility Analytics Raise Ranking of Johnson & Johnson (JNJ) to Strong Buy
investorplace.com - October 27 at 7:21 AM
[$$] A Talcum Powder Tort Blowout[$$] A Talcum Powder Tort Blowout
finance.yahoo.com - October 27 at 1:24 AM
Analyst Recommendations for Valeant Pharmaceuticals in OctoberAnalyst Recommendations for Valeant Pharmaceuticals in October
finance.yahoo.com - October 26 at 3:17 PM
Johnson & Johnson to Participate in the 26th Annual Credit Suisse Health Care ConferenceJohnson & Johnson to Participate in the 26th Annual Credit Suisse Health Care Conference
finance.yahoo.com - October 26 at 3:17 PM
Better Buy: Johnson & Johnson vs. PfizerBetter Buy: Johnson & Johnson vs. Pfizer
www.fool.com - October 25 at 7:44 AM
After The Earnings, I Prefer Johnson & Johnson, But Procter & Gamble Is A Better DealAfter The Earnings, I Prefer Johnson & Johnson, But Procter & Gamble Is A Better Deal
seekingalpha.com - October 25 at 2:58 AM

Social Media

Financials

Chart

Johnson & Johnson (NYSE JNJ) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.